Hexarelin vs Ipamorelin: Comparing the Indexed Record
The practical distance between Hexarelin and Ipamorelin shows up first in how much published methodology exists for each.
Compound profiles
Hexarelin in the indexed record
Hexarelin returns 313 indexed records on PubMed, a moderate record with no registered studies currently listed on ClinicalTrials.gov.
Recent indexed work appears in Drug Target Insights, Endocrine, Eur J Med Res, spanning 2014–2023.
- Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway — Eur J Med Res, 2023. PMID: 37710348
- The cardiovascular action of hexarelin — J Geriatr Cardiol, 2014. PMID: 25278975
- Hexarelin protects cardiac H9C2 cells from angiotensin II-induced hypertrophy via the regulation of autophagy — Pharmazie, 2019. PMID: 31526442
- Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury — Drug Target Insights, 2021. PMID: 34871336
Ipamorelin in the indexed record
Indexed output for Ipamorelin stands at 54 records, a moderate literature, alongside 3 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Am J Sports Med, Eur J Endocrinol, J Am Acad Orthop Surg Glob Res Rev, spanning 1998–2026.
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians — Am J Sports Med, 2026. PMID: 41476424
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions — J Am Acad Orthop Surg Glob Res Rev, 2026. PMID: 41490200
- Ipamorelin, the first selective growth hormone secretagogue — Eur J Endocrinol, 1998. PMID: 9849822
- A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — J Sports Med Phys Fitness, 2026. PMID: 41880199
How the literature differs
The indexed record is not symmetrical between these two compounds. Hexarelin carries 259 more indexed records than Ipamorelin, which means published methodology, characterisation data and replication attempts are more readily located for Hexarelin. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (0 vs 3) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Hexarelin | Ipamorelin |
|---|---|---|
| PubMed indexed records | 313 | 54 |
| Registered studies (ClinicalTrials.gov) | 0 | 3 |
| Literature depth | Moderate | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Hexarelin and Ipamorelin sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Hexarelin describes conditions validated for Hexarelin: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to Ipamorelin without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Selecting between them for a study design
Hexarelin and Ipamorelin are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Hexarelin) generally offers more methodological precedent.
Frequently asked questions
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Are Hexarelin and Ipamorelin the same compound?
No. They are structurally distinct research compounds with separate literature records — 313 indexed records for Hexarelin and 54 for Ipamorelin.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Related references
- Ipamorelin — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.